论文部分内容阅读
目的:研究EphA2和Ephri-nA1蛋白在乳腺癌组织中的表达及其意义。方法:用免疫组织化学SP法检测130例乳腺癌组织中EphA2和Ephri-nA1的蛋白表达水平及其与临床病理因素的关系。结果:130例乳腺癌组织中,EphA2和EphrinA1蛋白的阳性表达率分别为72.31%和59.23%;EphA2蛋白在乳腺癌的阳性表达率与临床分期、淋巴结转移和组织学分级显著相关,P<0.05。EphrinA1蛋白的阳性表达率与临床分期、组织学分级显著相关,P<0.05。EphA2和EphrinA1蛋白阳性染色共同定位于大致相同的肿瘤区域和血管内皮细胞,两者在乳腺癌组织中的阳性表达显著相关,P<0.05。结论:E-phA2和EphrinA1可能与乳腺癌的发生发展有关。它们的联合检测有助于客观评估乳腺癌的生物学行为,可用来指导临床用药和预测预后。
Objective: To study the expression of EphA2 and Ephri-nA1 in breast cancer and its significance. Methods: The protein expression of EphA2 and Ephri-nA1 in 130 cases of breast cancer was detected by immunohistochemical SP method and its relationship with clinicopathological factors. Results: The positive expression rates of EphA2 and EphrinA1 in 130 cases of breast cancer were 72.31% and 59.23%, respectively. The positive rates of EphA2 protein in breast cancer were significantly correlated with clinical stage, lymph node metastasis and histological grade, P <0.05 . The positive expression rate of EphrinA1 protein was significantly correlated with clinical stage and histological grade (P <0.05). EphA2 and EphrinA1 protein positive staining located in approximately the same tumor area and vascular endothelial cells, both in breast cancer positive expression was significantly correlated, P <0.05. Conclusion: E-phA2 and EphrinA1 may be related to the occurrence and development of breast cancer. Their joint detection helps to objectively assess the biological behavior of breast cancer, can be used to guide the clinical medication and predict prognosis.